WuXi Biologics (Cayman) Aktie WKN: A2DS7Z ISIN: KYG970081090 Kürzel: 1FW

Börse
Tradegate

Kurs zur WUXI BIOLOGICS DL-,000025 Aktie

23,00 EUR

-3,36 % -0,80 EUR

Login

Kursdaten

Geld (Stk.) 22,400 (247)
Brief (Stk.) 23,600 (247)
Spread 5,085
Geh. Stück 3.119 Stk
Eröffnung 23,400
Vortag 23,800
52 Wochen Hoch 25,000
52 Wochen Tief 9,500

Stand: 26.10.2020 - 22:01:39 Uhr

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker

Community-Beiträge (102)

Neu laden

Alle Kommentare Neu laden

k
kid heute 14:29 Uhr

Weiß oder hat einer Kursziele für die Firma ?

Summer.76
Summer.76 vom 23.10.20 22:51 Uhr

NOTICE OF EXTRAORDINARY GENERAL MEETING (will be held at the meeting room of Sheraton Shanghai Waigaoqiao Hotel, November 12, 2020 at 3:00 p.m.) https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a201023.pdf PROPOSED SHARE SUBDIVISION AND NOTICE OF EXTRAORDINARY GENERAL MEETING https://doc.irasia.com/listco/hk/wuxibiologics/circulars/c201023.pdf FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, NOVEMBER 12, 2020 https://doc.irasia.com/listco/hk/wuxibiologics/circulars/c201023a.pdf

Summer.76
Summer.76 vom 21.10.20 14:51 Uhr

Gutes Timing! Mal sehen, wie sich der beabsichtigte Split auswirken wird.

S
SeanP vom 21.10.20 13:54 Uhr

👌 Hatte erst gestern nachgelegt...

Summer.76
Summer.76 vom 21.10.20 08:34 Uhr

https://www.marketscreener.com/quote/stock/WUXI-BIOLOGICS-CAYMAN-I-37230806/news/WuXi-Biologics-Cayman-Shares-Soar-on-Upbeat-Revenue-Guidance-China-s-Vaccine-Progress-31579102/ ... The company's share price surge also came as Chinese authorities on Tuesday provided an upbeat update on the country's vaccine development, projecting annual production capacity to reach 610 million units by year-end.

Summer.76
Summer.76 vom 21.10.20 07:00 Uhr

WuXi Biologics (02269.HK) launches new strategy and benefits from the new crown project management expected to increase revenue by 50% next year http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1050203/popular-news An analyst meeting was held yesterday (20th) to update the company’s operations. The company’s management explained its new strategy "drug molecule". This is the company’s most recent Win more late-stage contracts than peers. The company’s management stated that due to multiple new coronavirus-related projects and its “drug molecule” strategy, the management expects that the company’s revenue in the second half of this year will grow by 40% year-on-year, and it is expected that revenue will grow by 50% in 2021, and will be in 2022 The annual growth target is set at 40%. According to the bank, WuXi Biologics has perfected its "drug molecule" strategy, and the backlog of orders growth is moving toward the bank's expectations, which is expected to reach 10.273 billion US dollars, which is a 101% increase so far this year. In addition, the company also signed a new coronavirus vaccine agreement worth up to 400 million U.S. dollars, indicating that the relevant data once again strengthened the bank's confidence in WuXi Bioenergy's recognition of global customers. According to the bank, under the new strategy, WuXi Biologics will have 10 pharmaceutical contract customized research and development manufacturing enterprises (CDMOs) by 2020 (providing multinational pharmaceutical companies and biotech companies with the process development and preparation of pharmaceuticals, especially innovative drugs). Project transfer is higher than the number of external projects added in all previous years. Of these 10 projects, 6 are in phase III clinical trials, and 1 is related to the new coronavirus, which indicates the recent revenue growth trend. The company's management pointed out that the newly established dual-strategy structure is based on WuXi's leading technology and industry capabilities. The bank is very optimistic about the potential synergy brought by the company's new strategic combination. Yamato believes that WuXi Biologics has a strong ability to deal with the new coronavirus pandemic, and pointed out that the company has added 72 new projects this year (62 in the first phase), setting a record in the company's history. It is worth noting that the company successfully signed another vaccine agreement worth up to 400 million US dollars. The total number of projects currently under preparation reaches 312, an increase of 25% over the year to date. Driven by newly added projects, especially more than 20 new coronavirus-related projects ($528 million have been signed and about US$500 million under discussion), it is estimated that the company’s outstanding service orders from the new crown virus project may be available. Reached $1 billion.

Summer.76
Summer.76 vom 21.10.20 06:45 Uhr

http://www.aastocks.com/en/stocks/news/aafn-con/now.1050230/latest-news Macquarie Lifts WUXI BIO (02269.HK) TP by 25% to $262.05, Seen as Sector Top Pick

Summer.76
Summer.76 vom 21.10.20 06:41 Uhr

G Sachs: WUXI BIO New Strategy Becomes Growth Driver; Mgmt Tweaks Up 21E Earing Growth Guidance http://www.aastocks.com/en/stocks/news/aafn-con/now.1050250/latest-news WUXI BIO (02269.HK) updated its operation position at an analyst meeting, Goldman Sachs mentioned in its report. At which, the management illustrated its latest strategy - "win-the-molecule" - for the first time, in hope of harvesting more market share by transferring projects from competitors. The broker believed the new strategy to become the company's future growth driver. In view of new strategy and more-than-expected contribution from Covid-19 related projects, the management hiked its 2021E earnings growth guidance to 50%+ YoY (from 40%+ previously).

Summer.76
Summer.76 vom 16.10.20 18:01 Uhr

https://bioprocessintl.com/bioprocess-insider/therapeutic-class/wuxi-cdmo-selection-the-last-barrier-to-adc-advancement/

Summer.76
Summer.76 vom 12.10.20 05:15 Uhr

WuXi Biologics steigt um über 4% und erreicht ein Rekordhoch https://finance.sina.cn/hkstock/sckxjfx/2020-10-12/detail-iivhuipp9154296.d.html?from=wap WuXi Biologics (02269.HK) stieg um mehr als 4% und erreichte ein Rekordhoch von 211,6 Hongkong-Dollar. Der Aktienkurs ist seit Ende März um mehr als 115% gestiegen.  ...

Alle Kommentare Neu laden

Neue Kommentare
1 WUXI BIOLOGICS DL-,000025 Hauptdiskussion

Geld/Brief Kurse

Börse Geld Brief Zeit Volumen Kurs
Frankfurt 23,00 24,20 1603732753 18:19 399 24,00 EUR
Berlin 22,00 23,60 1603734164 18:42 0 23,80 EUR
Düsseldorf 22,00 23,60 1603724425 16:00 0 23,20 EUR
München 23,02 23,68 1603695692 08:01 40 23,94 EUR
Stuttgart 22,40 23,60 1603696897 08:21 0 23,40 EUR
Nasdaq OTC 0,00 0,00 1603733822 18:37 275 29,06 USD
Tradegate 22,40 23,60 1603746099 22:01 3.119 23,00 EUR
Lang & Schwarz 22,60 23,40 1603745992 21:59 50 23,00 EUR
Gettex 22,98 23,71 1603744980 21:43 0 23,00 EUR
Baader Bank 22,98 23,71 1603738292 19:51 0 23,35 EUR

Realtime / Verzögert

WuXi Biologics (Cayman)

Börsennotierung

Marktkapitalisierung
31,292 Mrd EUR
Anzahl der Aktien
1,361 Mrd Stück

Grundlegende Daten zur WUXI BIOLOGICS DL-,000025 Aktie

Finanzdaten 2016 2017 2018 2019 2020 2021
Ergebnis je Aktie (bereinigt) - - - - - -
Cashflow - - - - - -
Eigenkapitalquote - - - - - -
Verschuldungsgrad - - - - - -
Eigenkapitalrendite - - - - - -
Gesamtkapitalrendite - - - - - -
EBITDA - - - - - -
EBIT - - - - - -
Fundamentaldaten 2016 2017 2018 2019 2020 2021
Dividendenrendite - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - -
Dividende je Aktie - - - - - -
Bilanzdaten 2016 2017 2018 2019 2020 2021
Netto-Provisionsüberschuss - - - - - -
Umsatzerlöse - - - - - -
Ergebnis vor Steuern - - - - - -
Steuern - - - - - -
Ausschüttungssumme - - - - - -
Nettoverzinsung - - - - - -
Zinsertrag - - - - - -
Gesamtertrag - - - - - -